Gerrit Toenges

Gerrit Toenges

Auto-generated profile, based on publicly available information

Gerrit Toenges

Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CLChristian Labenz
Christian Labenz
JBJ. S. Baron
J. S. Baron
GTG. Toenges
G. Toenges
JSJ. M. Schattenberg
J. M. Schattenberg
MNM. Nagel
M. Nagel
MWM.‐A. Wörns
M.‐A. Wörns

7 November 2012 in The Plant Journal
Verified
Journal Article
Open access
PDF file
JMJohana C. Misas‐Villamil
Johana C. Misas‐Villamil
GTGerrit Toenges
Gerrit Toenges
IKIzabella Kolodziejek
Izabella Kolodziejek
ASAmir M. Sadaghiani
Amir M. Sadaghiani
FKFarnusch Kaschani
Farnusch Kaschani
RHRenier Van der Hoorn
Renier Van der Hoorn
Summary: Vacuolar processing enzymes (VPEs) are important cysteine proteases that are implicated in the maturation of seed storage proteins, and programmed cell death during plant–microbe interactions and development. Here, we introduce a specific, cell‐permeable, activity‐based probe for VPEs. This probe is highly specific for all four Arabidopsis VPEs, and labeling is activity‐dependent, as illustrated by sensitivity for inhibitors, pH and reducing agents. We show that the probe can be used for in vivo imaging and displays multiple active isoforms of VPEs in various tissues and in both monocot and dicot plant species. Thus, VPE activity profiling is a robust, simple and powerful tool for plant research for a wide range of applications. Using VPE activity profiling, we discovered that VPE activity is increased during infection with the oomycete pathogen Hyaloperonospora arabidopsidis (Hpa). The enhanced VPE activity is host‐derived and EDS1‐independent. Sporulation of Hpa is reduced on vpe mutant plants, demonstrating a role for VPE during compatible interactions that is presumably independent of programmed cell death. Our data indicate that, as an obligate biotroph, Hpa takes advantage of increased VPE activity in the host, e.g. to mediate protein turnover and nutrient release.

8 January 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
TUTimo Uphaus
Timo Uphaus
MWMark Weber-Krüger
Mark Weber-Krüger
MGMartin Grond
Martin Grond
GTGerrit Toenges
Gerrit Toenges
AJAntje Jahn-Eimermacher
Antje Jahn-Eimermacher
KGKlaus Gröschel
Klaus Gröschel
Objective Prolonged monitoring times (72 hours) are recommended to detect paroxysmal atrial fibrillation (pAF) after ischemic stroke but this is not yet clinical practice; therefore, an individual patient selection for prolonged ECG monitoring might increase the diagnostic yield of pAF in a resource-saving manner. Methods We used individual patient data from 3 prospective studies (ntotal = 1,556) performing prolonged Holter-ECG monitoring (at least 72 hours) and centralized data evaluation after TIA or stroke in patients with sinus rhythm. Based on the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) guideline, a clinical score was developed on one cohort, internally validated by bootstrapping, and externally validated on 2 other studies. Results pAF was detected in 77 of 1,556 patients (4.9%) during 72 hours of Holter monitoring. After logistic regression analysis with variable selection, age and the qualifying stroke event (categorized as stroke severity with NIH Stroke Scale [NIHSS] score ≤5 [odds ratio 2.4 vs TIA; 95% confidence interval 0.8–6.9, p = 0.112] or stroke with NIHSS score >5 [odds ratio 7.2 vs TIA; 95% confidence interval 2.4–21.8, p < 0.001]) were found to be predictive for the detection of pAF within 72 hours of Holter monitoring and included in the final score (Age: 0.76 points/year, Stroke Severity NIHSS ≤5 = 9 points, NIHSS >5 = 21 points; to Find AF [AS5F]). The high-risk group defined by AS5F is characterized by a predicted risk between 5.2% and 40.8% for detection of pAF with a number needed to screen of 3 for the highest observed AS5F points within the study population. Regarding the low number of outcomes before generalization of AS5F, the results need replication. Conclusion The AS5F score can select patients for prolonged ECG monitoring after ischemic stroke to detect pAF. Classification of evidence This study provides Class I evidence that the AS5F score accurately identifies patients with ischemic stroke at a higher risk of pAF.

1 February 2019 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
CLChristian Labenz
Christian Labenz
LBLarissa Beul
Larissa Beul
GTGerrit Toenges
Gerrit Toenges
JSJörn M. Schattenberg
Jörn M. Schattenberg
MNMichael Nagel
Michael Nagel
MWMarcus-Alexander Wörns
Marcus-Alexander Wörns

18 February 2019 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
CLChristian Labenz
Christian Labenz
GTGerrit Toenges
Gerrit Toenges
YHYvonne Huber
Yvonne Huber
MNMichael Nagel
Michael Nagel
JMJens U. Marquardt
Jens U. Marquardt
MWMarcus-Alexander Wörns
Marcus-Alexander Wörns
OBJECTIVES: Diagnosis of covert hepatic encephalopathy (CHE) is challenging and often neglected in clinical practice. The aim of this study was to develop an easy-to-perform score to predict CHE in patients with cirrhosis. METHODS: For the development or validation cohort of the proposed clinical CHE score, 142 or 96 consecutive patients with cirrhosis were prospectively enrolled. The Psychometric Hepatic Encephalopathy Score was used to detect minimal hepatic encephalopathy. All patients were examined with the simplified animal naming test and were asked to complete the Chronic Liver Disease Questionnaire. We followed the TRIPOD guideline for development, validation, and reporting of the proposed score. RESULTS: The clinical covert hepatic encephalopathy score containing the variables—clinically detectable ascites, history of overt hepatic encephalopathy (OHE), albumin serum level, activity subdomain of the Chronic Liver Disease Questionnaire, and simplified animal naming test—discriminated best between patients with and without CHE. We generated 2 cutoff values for the identification of the high-, intermediate- (with need for additional specialized testing), and low-risk groups for CHE. By applying these cutoffs, the sensitivity, specificity, positive predictive value, and negative predictive value were 90%, 91%, 85%, and 94%, respectively. The AUC was 0.908 or 0.872 for the development or the validation cohort, respectively. Higher scores were further associated with poorer quality of life, and the high-risk group was predictive for first-time OHE within 180 days. CONCLUSIONS: We developed an easy-to-perform score to identify patients with cirrhosis at risk of CHE, which correlates with quality of life and risk of first-time OHE.

1 September 2021 in The Lancet Haematology
Verified
Journal Article
Closed access
GTGerrit Toenges
Gerrit Toenges
AMAnna C Mavromanoli
Anna C Mavromanoli
SBStefano Barco
Stefano Barco
WAWalter Ageno
Walter Ageno
HBHélène Bouvaist
Hélène Bouvaist
AWAnamaria Wolf-Pütz
Anamaria Wolf-Pütz